Skip to main content
FOCIS 2023 Main banner
Back
ViewAttendees 4

Session: Tolerance Therapeutics

Re-programing Autoreactivity to Suppress Autoimmunity

Wednesday, June 21, 2023
2:20 PM – 2:45 PM  
Location: Salon H-K
Disclosure(s):
Pere Santamaria, MD, PhD: Parvus Therapeutics: Employee (Ongoing), Equity/Owner (Ongoing), Grant Support (Ongoing), Patents/Royalty (Ongoing)

Learning Objectives:

  • The attendee will appreciate how pMHC-based nanomedicines were discovered.
  • The attendee will understand the key fundamental engineering principles that make these compounds work.
  • The attendee will learn how this new class of drugs can be used to re-program pathogenic autoimmunity to suppress specific autoimmune diseases.

Back to Top